In epithelial cancers, the abnormal expression of N-cadherin is associated with the loss of E-cadherin, a process named cadherin switch, which is a hallmark of the epithelial-mesenchymal transition reported in different cancers and in bladder cancer [4]. Here, CDH2 is linked to urinary bladder carcinoma.